Published 2026-05-22
Summary: CVC Capital Partners has made a full-takeover offer for Recordati, valuing the Italian drugmaker at €10.9 billion (about $12 billion), with the intention of delisting Recordati from the Italian stock exchange. CVC already owns a 47% stake in the company.
What We Know
- The takeover bid values Recordati at €10.9 billion (approximately $12.0 billion according to reports).
- CVC Capital Partners has offered to acquire the remaining shares of Recordati, aiming to delist the company from the Italian stock exchange.
- CVC Capital Partners already owned about 47% of Recordati at the time of the bid.
- The offer is described as a full takeover by CVC.
What’s Still Unclear
- Whether the €10.9 billion figure is final or subject to adjustments across sources.
- Specific terms of the deal beyond delisting and ownership stake are not detailed in the available information.
Context
Recordati is a family-run Italian pharma group with a long history. Private equity interest in European pharmaceutical companies and delisting scenarios are common strategic moves that can shift ownership, governance, and liquidity for shareholders.
Why It Matters
The bid, if completed, could change the control dynamics of Recordati and affect its strategic direction, potential changes in governance, and the options available to remaining shareholders. Delisting would remove the company from public markets, impacting liquidity and disclosure requirements.
What to Watch Next
- Official responses from Recordati’s board and major shareholders to the takeover proposal.
- Regulatory approvals and antitrust considerations in relevant jurisdictions.
- Any revised bid terms or competing offers from other buyers.
- Timeline for due diligence, negotiations, and potential closing of the deal.
FAQ
Q: What is the estimated value of the Recordati takeover bid?
A: The bid values Recordati at €10.9 billion, about $12.0 billion depending on exchange rates.
Q: Who is making the takeover offer?
A: Private equity firm CVC Capital Partners.
Related coverage
- Turkey market turbulence leadership crisis: policymakers
- SOL Eyes Mixed Technicals as ETF Flows Provide Contextual
- LINK technical analysis: ETF flows in focus
Source Transparency
- This article is based on a short preliminary brief and may not reflect the full details available in ongoing reporting.
- Source links are provided in the Sources section where available.
- A limited open-web check was used to clarify key details when possible; unclear items remain clearly marked.
Original brief: CVC and GBL offer to buy Recordati in a deal valuing the Italian drugmaker at more than $12 billion…
Sources
- CVC Capital offers $12.6B to buy out Italian pharma Recordati
- Recordati gets €10.9bn takeover bid from private equity firm
- Recordati confirms 10.9 billion euro full takeover offer from CVC
- Recordati says it's received a $12B+ takeover bid
- Recordati sizes up €10.9bn CVC Capital acquisition offer